Evermay Wealth Management’s GSK GSK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$29.1K Sell
598
-504
-46% -$25.7K ﹤0.01% 400
2026
Q2
$58K Buy
1,102
+904
+457% +$47.8K 0.01% 338
2026
Q1
$11K Hold
198
– – ﹤0.01% 454
2025
Q4
$9.8K Hold
198
– – ﹤0.01% 449
2025
Q3
$8.63K Hold
198
– – ﹤0.01% 455
2025
Q2
$7.69K Hold
198
– – ﹤0.01% 460
2025
Q1
$7.75K Hold
198
– – ﹤0.01% 465
2024
Q4
$6.77K Hold
198
– – ﹤0.01% 474
2024
Q3
$8.17K Hold
198
– – ﹤0.01% 473
2024
Q2
$7.7K Hold
198
– – ﹤0.01% 475
2024
Q1
$8.57K Hold
198
– – ﹤0.01% 483
2023
Q4
$7.41K Hold
198
– – ﹤0.01% 468
2023
Q3
$7.25K Hold
198
– – ﹤0.01% 454
2023
Q2
$7.13K Hold
198
– – ﹤0.01% 448
2023
Q1
$7.11K Hold
198
– – ﹤0.01% 441
2022
Q4
$7.02K Hold
198
– – ﹤0.01% 442
2022
Q3
$6K Hold
198
– – ﹤0.01% 437
2022
Q2
$11K Hold
198
– – ﹤0.01% 385
2022
Q1
$11K Hold
198
– – ﹤0.01% 412
2021
Q4
$11K Hold
198
– – ﹤0.01% 400
2021
Q3
$9K Sell
198
-320
-62% -$16.1K ﹤0.01% 390
2021
Q2
$26K Buy
+518
New +$24.9K ﹤0.01% 337

Other funds holding GSK

Evermay Wealth Management's GSK Position: Q3 2026 in Review

Evermay Wealth Management reduced its GSK (GSK) stake by 46% in Q3 2026, selling an estimated $25.7K and leaving 598 shares worth $29.1K. The position accounts for ﹤0.01% of the portfolio, ranked #400.

Evermay Wealth Management first reported a position in GSK in Q2 2021 and has held it in 22 quarters since. The position peaked at $58K in Q2 2026. 981 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Evermay Wealth Management held 598 shares of GSK worth $29.1K as of Q3 2026.
  • Evermay Wealth Management sold 504 GSK shares in Q3 2026, an estimated $25.7K.
  • GSK made up ﹤0.01% of Evermay Wealth Management's portfolio in Q3 2026, its #400 holding.
  • Evermay Wealth Management first reported a position in GSK in Q2 2021 and has held it in 22 quarters since.
  • Evermay Wealth Management's GSK position peaked at $58K in Q2 2026.
  • 981 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Evermay Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.